Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have histologically or cytologically confirmed Acute Myeloid Leukemia, as defined by the WHO classification.~2. Patients must be considered unfit for conventional induction chemotherapy, unwilling to receive such treatment or have evidence of disease relapse or refractory disease.~3. For patients who have received no prior conventional chemotherapy, one of the following must be present:~   * Poor risk cytogenetics (complex abnormalities, deletions of chromosome 7 or 5, 11q23 abnormalities, inv\[3\])~  * Secondary leukemia (prior hematologic disorder or therapy-related leukemia).~4. Age \> 60 years of age.~5. Life expectancy of greater than 3 months.~6. ECOG performance status greater than 2.~7. Patients must have normal organ and marrow function as defined below:~8. Adequate hepatic function: Total bilirubin 1.5mg/dL, AST(SGOT)/ALT(SGPT) 2.5 X institutional upper limit of normal.~9. Adequate renal function: serum creatinine within normal institutional limits or Calculated creatinine clearance \> 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.~10. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.~2. Patients may not be receiving any other investigational agents.~3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or DTIC~4. History of gastrointestinal disease or significant bowel resection that could interfere with drug absorption.~5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~6. Prior allogeneic stem cell transplantation.~7. Inability to swallow tablets~8. Prior radiation up to more than 25% of bone marrow.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylated AGAT Promoter (Group 1) (Type: EXPERIMENTAL): Induction: 200 mg/m2/day oral Temozolomide x 7 days
- Un-Methylated AGAT Promoter (Group 2) (Type: EXPERIMENTAL): Priming: 100 mg/m2/day oral Temozolomide x 14 days, followed by Induction: 200 mg/m2/day oral Temozolomide x 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).